HBM Holdings Forecasts Sharp Profit Surge on Recurring Biotech Collaboration Revenue

HBM Holdings Ltd. ( (HK:2142) ) has issued an update.

HBM Holdings Limited has issued a positive profit alert, indicating that its unaudited profit for the year ended 31 December 2025 is expected to surge to between US$88 million and US$95 million, compared with US$2.7 million a year earlier, with total adjusted profit forecast at US$91 million to US$98 million. Management attributes this sharp improvement to continued growth in recurring revenue from major global research collaborations, the successful conversion of out-licensing and product collaborations into stable revenue streams, and rapid expansion at subsidiary Nona Biosciences, which has contributed technology licence, platform service and milestone income, underscoring the Group’s strengthening commercialisation capabilities and deepening integration into the global biopharma value chain.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

More about HBM Holdings Ltd.

HBM Holdings Limited is a Cayman Islands-incorporated company listed on the Stock Exchange of Hong Kong, operating in the biopharmaceutical and life sciences sector. The Group focuses on platform-based research collaborations with global pharmaceutical companies and out-licensing of innovative products, with a growing base of recurring revenue from technology licences, platform services and milestone payments generated through partners such as AstraZeneca, Bristol Myers Squibb, Otsuka Pharmaceutical, Windward Bio and Pfizer.

Average Trading Volume: 4,580,667

Technical Sentiment Signal: Buy

Current Market Cap: HK$10.51B

See more insights into 2142 stock on TipRanks’ Stock Analysis page.